Steve E. Krognes Sells 688 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes sold 688 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $21.79, for a total value of $14,991.52. Following the transaction, the director now directly owns 52,620 shares in the company, valued at $1,146,589.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Denali Therapeutics Price Performance

DNLI stock opened at $21.30 on Friday. Denali Therapeutics Inc. has a 12-month low of $14.56 and a 12-month high of $30.79. The stock’s 50 day simple moving average is $19.93 and its 200 day simple moving average is $19.30.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. During the same period in the prior year, the company earned ($0.80) EPS. On average, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DNLI shares. Stifel Nicolaus reduced their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and set a $95.00 price target on shares of Denali Therapeutics in a research report on Wednesday, May 8th. UBS Group reduced their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Finally, Wedbush reduced their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $40.22.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DNLI. Hsbc Holdings PLC bought a new position in Denali Therapeutics during the 3rd quarter worth $359,000. Northern Trust Corp grew its stake in Denali Therapeutics by 2.5% during the 3rd quarter. Northern Trust Corp now owns 1,116,742 shares of the company’s stock worth $23,038,000 after buying an additional 27,044 shares during the last quarter. Teza Capital Management LLC bought a new position in Denali Therapeutics during the 3rd quarter worth $446,000. Gotham Asset Management LLC bought a new position in Denali Therapeutics during the 3rd quarter worth $400,000. Finally, Alps Advisors Inc. grew its stake in Denali Therapeutics by 0.8% during the 3rd quarter. Alps Advisors Inc. now owns 101,400 shares of the company’s stock worth $2,092,000 after buying an additional 780 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.